PIONEER big data platform for prostate cancer: lessons for advancing future real-world evidence research

Publikation: Beitrag in FachzeitschriftForschungsartikelBeigetragenBegutachtung

Beitragende

  • The PIONEER Consortium - (Autor:in)
  • Klinik und Poliklinik für Urologie
  • King's College London (KCL)
  • Erasmus University Rotterdam
  • Collaborate Project Management UG
  • Lund University
  • Institut Européen pour la Biologie des Systèmes et la Médecine (EISBM)
  • University of Aberdeen
  • Koninklijke Philips N.V.
  • Rotterdam University of Applied Sciences
  • Bayer AB
  • European Association of Urology (EAU)
  • Hospital Clinico Universitario San Carlos
  • Vita-Salute San Raffaele University
  • Università degli Studi di Firenze
  • Hippokration General Hospital
  • ARTTIC Innovation GmbH
  • Bayer AG
  • Pinsent Masons LLP
  • Astellas Pharma Inc.
  • The Hyve
  • European Alliance for Personalized Medicine
  • IQVIA Inc.
  • Ludwig-Maximilians-Universität München (LMU)
  • Helmholtz-Zentrum Dresden-Rossendorf (HZDR)
  • AstraZeneca
  • Ecancer
  • Johnson & Johnson
  • SAS Belgium
  • Sanofi S.A.
  • Institutet för Hälso- och Sjukvårdsekonomi (IHE)
  • Radboud University Nijmegen
  • University of Gothenburg
  • Fraunhofer-Institut für Zelltherapie und Immunologie
  • Klinik und Poliklinik für Urologie

Abstract

Prostate Cancer Diagnosis and Treatment Enhancement through the Power of Big Data in Europe (PIONEER) is a European network of excellence for big data in prostate cancer. PIONEER brings together 34 private and public stakeholders from 9 countries in one multidisciplinary research consortium with the aim of positively transforming the field of prostate cancer clinical care by answering pressing questions related to prostate cancer screening, diagnosis and treatment. PIONEER has developed a unique state-of-the-art big data analytic platform by integrating existing data sources from patients with prostate cancer. PIONEER leveraged this platform to address prioritized research questions, filling knowledge gaps in the characterization, management and core outcomes of prostate cancer across the different disease stages. The network has benefited from sustained patient and stakeholder involvement and engagement, but many challenges remain when using real-world data for big data projects. To continue to advance prostate cancer care, data need to be available, suitable methodologies should be selected and mechanisms for knowledge sharing must be in place. Now acting as the prostate cancer arm of the European Association of Urology’s new endeavour, UroEvidenceHub, PIONEER maintains its goal of maximizing the potential of big data to improve prostate cancer care.

Details

OriginalspracheEnglisch
Aufsatznummere058267
Seiten (von - bis)116-124
Seitenumfang9
FachzeitschriftNature Reviews Urology
Jahrgang22
Ausgabenummer2
PublikationsstatusVeröffentlicht - Feb. 2025
Peer-Review-StatusJa

Schlagworte

Ziele für nachhaltige Entwicklung

ASJC Scopus Sachgebiete